HCW Biologics (NASDAQ:HCWB – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($2.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($1.48), FiscalAI reports. HCW Biologics had a negative net margin of 83.03% and a negative return on equity of 262.33%. The company had revenue of $0.06 million during the quarter, compared to analyst estimates of $0.12 million.
HCW Biologics Stock Performance
Shares of NASDAQ HCWB opened at $0.77 on Monday. HCW Biologics has a 12 month low of $0.76 and a 12 month high of $23.94. The stock has a 50 day moving average of $1.52 and a 200-day moving average of $3.82. The company has a market capitalization of $1.73 million, a P/E ratio of -0.03 and a beta of 2.31.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on the company. Wall Street Zen upgraded HCW Biologics from a “sell” rating to a “hold” rating in a report on Saturday, October 31st. Weiss Ratings reissued a “sell (e+)” rating on shares of HCW Biologics in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $30.00.
HCW Biologics Company Profile
HCW Biologics Inc. (NASDAQ: HCWB) is a clinical-stage biotechnology company focused on developing immunotherapies for diseases associated with chronic inflammation, immune dysfunction and aging. The company’s research is intended to address conditions in which persistent inflammation contributes to disease progression. HCW Biologics uses its proprietary TOBI platform to design multifunctional fusion proteins that can target inflammatory pathways and modify immune responses. Its development programs have included HCW9218, an investigational immunotherapy designed to combine immune-stimulating activity with inhibition of transforming growth factor beta, a signaling pathway associated with immune suppression and disease progression.
Further Reading
- Five stocks we like better than HCW Biologics
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
